[Pubmed] Plasma Exchange in Patients With Myositis due to Immune Checkpoint Inhibitor Therapy

[RSS-Bot]

J Clin Neuromuscul Dis. 2023 Dec 1;25(2):89-93. doi: 10.1097/CND.0000000000000457. Epub 2023 Nov 13.

ABSTRACT

Immune checkpoint inhibitors used to treat malignancies may lead to various immune-related adverse events (irAEs) including conditions such as myositis and myasthenia gravis (MG). Here, we describe 2 cases of myositis treated effectively with therapeutic plasma exchange (PLEX). A 64-year-old man with thymic cancer developed leg weakness and dyspnea 1 month after the second dose of nivolumab with moderate weakness in proximal and distal muscles, with elevated creatine kinase levels. Another 77-year-old man with Stage IIIB squamous cell carcinoma of the lung developed progressive proximal muscle weakness and became nonambulatory after cycle 2 of durvalumab with persistently high creatine kinase levels despite prednisone treatment. Electrophysiology revealed irritative myopathy without evidence of neuromuscular junction dysfunction and MG antibody testing was nonrevealing. With PLEX, both patients noticed rapid improvement in strength. PLEX in conjunction with other immunosuppressive agents can result in rapid improvement in irAE-myositis even in patients without associated MG.

PMID:37962196 | DOI:10.1097/CND.0000000000000457


Source: https://pubmed.ncbi.nlm.nih.gov/3796219 ... t6+86293ac